CG Oncology (NASDAQ:CGON - Get Free Report) had its target price boosted by investment analysts at Morgan Stanley from $102.00 to $117.00 in a report released on Wednesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Morgan Stanley's price objective points to a potential upside of 47.90% from the stock's previous close.
CGON has been the topic of several other reports. Truist Financial restated a "buy" rating and issued a $100.00 price target (up from $85.00) on shares of CG Oncology in a research report on Tuesday. Wedbush upped their price objective on shares of CG Oncology from $84.00 to $91.00 and gave the company an "outperform" rating in a research report on Tuesday. Royal Bank Of Canada downgraded CG Oncology from an "outperform" rating to a "sector perform" rating and raised their price objective for the stock from $80.00 to $97.00 in a research report on Tuesday. HC Wainwright lifted their target price on shares of CG Oncology from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CG Oncology in a research note on Thursday, October 15th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $98.78.
View Our Latest Stock Analysis on CGON
CG Oncology Price Performance
Shares of CG Oncology stock traded up $0.17 during midday trading on Wednesday, hitting $79.11. The company had a trading volume of 112,946 shares, compared to its average volume of 1,148,053. The business's 50 day simple moving average is $68.35 and its two-hundred day simple moving average is $66.82. The stock has a market cap of $7.07 billion, a PE ratio of -28.59 and a beta of 0.35. CG Oncology has a 1-year low of $37.01 and a 1-year high of $93.95.
CG Oncology (NASDAQ:CGON - Get Free Report) last released its earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.19. The firm had revenue of $1.60 million during the quarter, compared to analysts' expectations of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. On average, sell-side analysts expect that CG Oncology will post -2.97 EPS for the current fiscal year.
Insider Transactions at CG Oncology
In related news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $92.00, for a total transaction of $92,000.00. Following the completion of the transaction, the director directly owned 1,000 shares of the company's stock, valued at $92,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 3,000 shares of company stock worth $227,040. Company insiders own 4.80% of the company's stock.
Institutional Trading of CG Oncology
Large investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd acquired a new position in CG Oncology during the 2nd quarter worth about $718,000. Legal & General Group Plc bought a new stake in CG Oncology during the 2nd quarter worth about $2,846,000. Jefferies Financial Group Inc. bought a new stake in CG Oncology during the 2nd quarter worth about $54,705,000. Jupiter Topco LLC acquired a new stake in CG Oncology in the 2nd quarter valued at about $1,634,000. Finally, Bank of New York Mellon Corp acquired a new stake in CG Oncology in the 2nd quarter valued at about $16,584,000. 26.56% of the stock is owned by institutional investors.
Recent CG Oncology Headlines
Investors following CGON have been watching these headlines:
- Positive Sentiment: The PIVOT-006 Phase 3 trial reported a 68% reduction in bladder-cancer recurrence risk, strengthening the outlook for cretostimogene and driving investor interest. Reuters trial coverage
- Neutral Sentiment: The results are preliminary, with fuller data expected in December and planned BLA submissions in 2027; clinical details and regulatory progress remain key milestones. PIVOT-006 trial results
- Negative Sentiment: Director Leonard Post sold 1,000 shares for $92,000, cutting his direct stake by half. The transaction could weigh modestly on sentiment, though it is small relative to the company’s overall value. SEC ownership filing
CG Oncology Company Profile
(
Get Free Report)
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company's research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.